When India launched its COVID-19 vaccination drive in the middle of January, the chances of success looked high: It could produce more shots than any country in the world and had decades of experience inoculating pregnant women and babies in rural areas.
“Our preparation has been such that vaccine is fast reaching every corner of the country,” Indian Prime Minister Narendra Modi said on Jan. 22. “On the world’s biggest need today, we are completely self-reliant. Not just that, India is also helping out many countries with vaccines.”
Just more than three months later, that initial promise has evaporated and the government’s plans are in disarray. India has fully vaccinated less than 2 percent of its 1.3 billion population, inoculation centers across the country say they are running short of doses and exports have all but stopped. Rather than building protection, the South Asian nation is setting daily records for new infections as a second wave overwhelms hospitals and crematoriums.
Illustration: YUsha
Modi’s response has been to abruptly shift strategy on vaccines and supplies. Initially the federal government negotiated prices with manufacturers, distributed them to states, and restricted them to priority groups like the elderly and healthcare workers.
Starting on Saturday, everyone over 18 is eligible for a vaccine, while state governments and private hospitals can purchase doses directly from manufacturers for people from 18 to 45 years — triggering a desperate free-for-all rush to secure shots from an already strapped market.
His government has said the new rules make “pricing, procurement, eligibility and administration of vaccines open and flexible.”
Health experts and officials in opposition-controlled states have said the plan passes the buck to regional governments rather than addressing the COVID-19 pandemic directly.
Widening the rollout of shots is also questionable when India is running low on stocks, with developers like Serum Institute of India Ltd saying the US has been hoarding ingredients and new supplies could potentially be months away.
’NO DISCUSSION’
“There was no discussion with state governments before asking states to procure vaccines on their own,” Chhattisgarh State Minister of Health T.S. Singh Deo said. “As a state we will have to buy vaccines from the open market, severely denting our finances.”
Given India’s growing strategic importance, its wave of infections risks not only the fledgling recovery in Asia’s third-largest economy, but attempts to tamp down COVID-19 and recuperate globally. The nation is now the main hotspot of the pandemic, despite being home to the world’s largest vaccine manufacturer.
“The vaccination program really should be a big focus,” said Raina MacIntyre, a professor of biosecurity at the University of New South Wales in Sydney. “Getting people vaccinated will also reduce the selective pressure for emergence of new strains.”
While it is easy to pinpoint now, the Modi government missed chances to concentrate on supporting vaccine production and scale up its decrepit health system. An over-reliance on an app-based technology made it hard for its poor and rural citizens to sign up, and Modi’s plan did not utilize India’s million-strong army of trained health workers — the Accredited Social Health Activists, or ASHAs — to reach its vast rural hinterland, a strategy that made its polio vaccination such a success.
WARNING SIGNS
Instead, government officials focused on making a show of India’s ability to help the world.
On Jan. 28, when Modi told the World Economic Forum’s virtual Davos Summit that India would assist other countries with vaccines, the daily case tally was 18,885 that day — compared with 379,257 on Thursday. By then, Serum and other vaccine developers were already warning about shortages and pointing the finger at the US. India slowed vaccine exports and expanded domestic inoculations to those 45 and over.
While the immunization plans of countries around the world took a hit, life in India was going on pretty much as normal. Millions of pilgrims took a dip in the holy Ganges River in the Hindu religious festival Kumbh Mela, while political parties held mass rallies in five state elections.
Less than six weeks later, Indian Minister of Health Harsh Vardhan said “we are in the end game of the COVID-19 pandemic in India.”
Even on March 30, when cases were again on the rise, Vardhan said “the situation is under control.”
“There is no COVID in Assam,” Himanta Biswa Sarma, a member of Modi’s party who serves as the state’s health minister, said on April 3. “There is no need to wear a face mask now.”
On April 16, shortages of doses had become so acute that Serum chief executive officer Adar Poonawalla tweeted directly at US President Joe Biden to ask him to lift the US embargo of raw material exports.
STATE BURDEN
Three days later, Modi abandoned his vaccine strategy and threw the burden on the states — many of which are frustrated. India effectively stopped shipping vaccines to elsewhere in the world, prompting its neighbors to seek help from China.
Kerala State Minister of Finance Thomas Isaac called Modi’s new vaccine plan a “clever political ploy” rather than a solution.
“There has been no coordination or consultation on how the vaccination policy will work,” said Balbir Singh Sidhu, the health minister of opposition Congress-run northern Punjab state. “It’s all top-down.”
A spokesperson from the Indian Ministry of Health did not respond to calls and e-mails seeking comment.
A big question now is how India can ramp up supply to provide vaccines to another 600 million people. Shortages are already apparent in the current program of giving shots to those aged 45 and over, causing vaccination rates to steadily dip across the country even as more then 10 million registered for doses in when the drive opened on Wednesday.
Officials from several states said India’s two vaccine suppliers — the Serum Institute, which produces the AstraZeneca shot, and Bharat Biotech International Ltd, making a domestically developed inoculation — have told them they can expect supplies for provincial governments from the middle of this month, even although those eligible can register for the shots from Wednesday.
‘PRICE SHOULD BE ZERO’
Both Serum and Bharat Biotech have said they can only ramp up capacity by July, with existing stock split equally between the center and the states.
New Delhi has cleared Russia’s Sputnik V for emergency use and news reports have said that some imports might come in this month, but there are no specifics on quantity. The US promised to send materials for India to make vaccines and share its stockpile of AstraZenaca vaccines, but details are unclear.
Then there is the cost. State governments were told they would have to pay between US$5 to US$8 for the shots, as much as three times what the federal government pays.
Following an outcry over the hikes, Bharat Biotech on Thursday announced that it would cut the amount it charges states to 400 rupees (US$5.40) a dose from 600 rupees, a day after Serum chief executive officer Adar Poonawalla said his company would reduce prices by 100 rupees.
Rajesh Tope, the health minister of Maharashtra — home to the country’s financial capital, Mumbai — said the state would spend 65 billion rupees to inoculate its residents for free, but cannot expand the program to all adults for now, because it does not have sufficient doses.
India was already one of few countries to allow private sales of COVID-19 shots, when it let private hospitals start inoculating at a fixed price of about US$3 a dose. Now the cost has risen to US$8 to US$16 a dose, meaning they administer them at even higher prices.
“There should be one price for vaccine jabs all over India,” Arvind Subramanian, former chief economic adviser to Modi’s administration, wrote on Twitter over the weekend. “That price should be zero.”
The US election result will significantly impact its foreign policy with global implications. As tensions escalate in the Taiwan Strait and conflicts elsewhere draw attention away from the western Pacific, Taiwan was closely monitoring the election, as many believe that whoever won would confront an increasingly assertive China, especially with speculation over a potential escalation in or around 2027. A second Donald Trump presidency naturally raises questions concerning the future of US policy toward China and Taiwan, with Trump displaying mixed signals as to his position on the cross-strait conflict. US foreign policy would also depend on Trump’s Cabinet and
The Taiwanese have proven to be resilient in the face of disasters and they have resisted continuing attempts to subordinate Taiwan to the People’s Republic of China (PRC). Nonetheless, the Taiwanese can and should do more to become even more resilient and to be better prepared for resistance should the Chinese Communist Party (CCP) try to annex Taiwan. President William Lai (賴清德) argues that the Taiwanese should determine their own fate. This position continues the Democratic Progressive Party’s (DPP) tradition of opposing the CCP’s annexation of Taiwan. Lai challenges the CCP’s narrative by stating that Taiwan is not subordinate to the
Republican candidate and former US president Donald Trump is to be the 47th president of the US after beating his Democratic rival, US Vice President Kamala Harris, in the election on Tuesday. Trump’s thumping victory — winning 295 Electoral College votes against Harris’ 226 as of press time last night, along with the Republicans winning control of the US Senate and possibly the House of Representatives — is a remarkable political comeback from his 2020 defeat to US President Joe Biden, and means Trump has a strong political mandate to implement his agenda. What does Trump’s victory mean for Taiwan, Asia, deterrence
The return of US president-elect Donald Trump to the White House has injected a new wave of anxiety across the Taiwan Strait. For Taiwan, an island whose very survival depends on the delicate and strategic support from the US, Trump’s election victory raises a cascade of questions and fears about what lies ahead. His approach to international relations — grounded in transactional and unpredictable policies — poses unique risks to Taiwan’s stability, economic prosperity and geopolitical standing. Trump’s first term left a complicated legacy in the region. On the one hand, his administration ramped up arms sales to Taiwan and sanctioned
RSS